DUBTAC in action against a target. (Courtesy Nomura Lab)
For some time, scientists have been working on the major challenge of developing new therapies against many human diseases. Many of these diseases are caused by the abberant action of certain proteins in our cells that are considered “undruggable”, or difficult to therapeutically target using classical drug...
The catalysis innovator on the thrills of heading to the mountains and having a reaction named after him.
John Hartwig is the Henry Rapoport Professor of Chemistry at the University of California, Berkeley. He received the 2019 Wolf Prize in Chemistry. His research aims to find new metal-catalysed reactions, and he was one of the developers of the Buchwald-...
UC Berkeley Office for the Vice Chancellor for Research | Press Release
Professor Kumar photographed at UC Berkeley. (Photo Annie Lin)
This week UC Berkeley’s office for the Vice Chancellor for Research announced that Professor Sanjay Kumar has been selected to serve as the next director of the...
David Schaffer, Professor of Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, and the Helen Wills Neuroscience Institute at U.C. Berkeley, gave a presentation during homecoming on the future of gene therapies and stem cell therapies. Viewed as the next stages of medical treatments, Prof. Schaffer discusses some of the exciting research coming from his lab.
